Patheon NV (PTHN) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Patheon NV (NASDAQ:PTHN) have earned an average rating of “Hold” from the nine brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $33.25.
PTHN has been the subject of several recent analyst reports. Jefferies Group LLC reissued a “hold” rating and issued a $35.00 price target on shares of Patheon NV in a report on Friday, July 21st. BidaskClub cut Patheon NV from a “sell” rating to a “strong sell” rating in a report on Saturday, September 2nd.
Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in shares of Patheon NV in the 2nd quarter valued at approximately $119,000. Seven Eight Capital LP acquired a new stake in shares of Patheon NV in the 2nd quarter valued at approximately $136,000. Pacad Investment Ltd. acquired a new stake in shares of Patheon NV in the 2nd quarter valued at approximately $164,000. Utah Retirement Systems acquired a new stake in shares of Patheon NV in the 2nd quarter valued at approximately $212,000. Finally, Amalgamated Bank acquired a new stake in shares of Patheon NV in the 2nd quarter valued at approximately $222,000.
Patheon NV (NASDAQ PTHN) remained flat at $34.98 during mid-day trading on Thursday. 229,751 shares of the company traded hands. Patheon NV has a 12-month low of $24.45 and a 12-month high of $35.02. The stock has a 50-day moving average price of $34.98 and a 200-day moving average price of $34.98. The stock has a market capitalization of $5.08 billion and a price-to-earnings ratio of 44.85.
About Patheon NV
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.